Article: 180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders

Article - Media, Publications

180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders

GLOBE NEWSWIRE, 24 March 2021

180 Life Sciences Corp. (NASDAQ: ATNF, the “Company”), a clinical-stage biotechnology company with its lead indication in Phase 2b/3 clinical trial, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today released the following letter to stockholders from its Chief Executive Officer, Dr. James Woody. Continue reading “Article: 180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders”

Article: Form 8-K 180 Life Sciences Corp.

Article - Media, Publications

Form 8-K 180 Life Sciences Corp.

EDGAR AGENTS LLC, 24 February 2021

On February 19, 2021, 180 Life Sciences Corp. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers identified on the signature pages thereto (the “Purchasers”) pursuant to which the Company agreed to sell to the Purchasers an aggregate of 2,564,000 shares (the “Shares”) of the common stock, par value $0.0001 per share, of the Company (“Common Stock”), and warrants to purchase up to an aggregate of 2,564,000 shares of Common Stock (the “Warrants”), at a combined purchase price of $4.55 per Share and accompanying Warrant (the “Offering”). Aggregate gross proceeds from the Offering are expected to be approximately $11.7 million, prior to deducting placement agent fees and estimated offering expenses payable by the Company. Net proceeds to the Company from the Offering, after deducting the placement agent fees and estimated offering expenses payable by the Company, are expected to be approximately $10.8 million. The Offering closed on February 23, 2021. Continue reading “Article: Form 8-K 180 Life Sciences Corp.”

THE DOLLAR HAS NO INTRINSIC VALUE : DO YOUR ASSETS?